Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
sintilimab + regorafenib + cetuximab
- Development stage
- Phase 2
- Lead developer
- Tianjin Medical University Cancer Institute and Hospital
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
A combination therapy consisting of sintilimab (PD-1 inhibitor), regorafenib (multi-kinase inhibitor with antiangiogenic properties), and cetuximab (EGFR inhibitor). This regimen is being investigated for the treatment of advanced colorectal cancer, particularly in patients with microsatellite stable (MSS) metastatic colorectal cancer who have failed previous lines of therapy. The combination aims to enhance antitumor effects through complementary mechanisms of action.
- Other names
- sintilimab + regofinib + cetuximabSintilimab combined with Regorafenib and Cetuximab
02
Targets
BRAF (B-Raf proto-oncogene, serine/threonine kinase)EGFR (Epidermal growth factor receptor)FGFR1 (Fibroblast growth factor receptor 1)FGFR2 (Keratinocyte growth factor receptor)KIT (c-KIT proto-oncogene receptor tyrosine kinase)PDGFRA (Platelet-derived growth factor receptor alpha)PDGFRB (Platelet-derived growth factor receptor beta)PDCD1 (Programmed cell death protein 1 receptor)RAF1 (c-Raf-1 (Y340D/Y341D))RET (Rearranged during transfection receptor tyrosine kinase)TEK (Tie2)VEGFR-1 (Vascular endothelial growth factor receptor 1)VEGFR2 (Vascular endothelial growth factor receptor 2)VEGFR4 (Vascular endothelial growth factor Receptor-3)
Beyond the preview
Go deeper on sintilimab + regorafenib + cetuximab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on sintilimab + regorafenib + cetuximab.